Autologous tumor cells engineered for immune system stimulation can target unique metabolic, genomic, and phenotypic characteristics of cancer cells.
Jon Weston
Advertisement
Jon Weston is the president and CEO of PhotonPharma.
Articles by Jon Weston
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
2
Amgen Real-World Study Links Evolocumab to Lower Heart Attack Risk Than Ezetimibe
3
UCB Reports 24-Week Bimekizumab (Bimzelx) vs Risankizumab Data in PsA
4
argenx Agrees to Buy Unnatural Products in Up to $1.15 Billion Deal
5